跳轉至內容
Merck

Enhanced activation of human NK cells by drug-exposed hepatocytes.

Archives of toxicology (2020-02-16)
Frank Fasbender, Martin Obholzer, Sarah Metzler, Regina Stöber, Jan G Hengstler, Carsten Watzl
摘要

Drug-induced liver injury (DILI) represents one of the major causes why drugs have to be withdrawn from the market. In this study, we describe a new interaction between drug-exposed hepatocytes and natural killer (NK) cells. In a previous genome-wide expression analysis of primary human hepatocytes that had been exposed to clinically relevant concentrations of 148 drugs, we found that several activating ligands for NK cell receptors were regulated by various drugs (e.g., valproic acid, ketoconazole, promethazine, isoniazid). Especially expression of the activating NKG2D ligands (MICA, MICB and ULBPs) and the NKp30 ligand B7-H6 were upregulated in primary human hepatocytes upon exposure to many different drugs. Using the human hepatocyte cell lines Huh7 and HepG2, we confirmed that protein levels of activating NK cell ligands were elevated after drug exposure. Hepatocyte cell lines or primary human hepatocytes co-cultivated with NK cells caused enhanced NK cell activation after pretreatment with drugs at in vivo relevant concentrations compared to solvent controls. Enhanced NK cell activation was evident by increased cytotoxicity against hepatocytes and interferon (IFN)-γ production. NK cell activation could be blocked by specific antibodies against activating NK cell receptors. These data support the hypothesis that NK cells can modulate drug-induced liver injury by direct interaction with hepatocytes resulting in cytotoxicity and IFN-γ production.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
乙酰水杨酸, ≥99.0%
Sigma-Aldrich
酮康唑, 99.0-101.0% (EP, titration)
Sigma-Aldrich
异丙嗪 盐酸盐
Supelco
异烟肼, analytical standard, ≥99% (TLC)
Supelco
丙戊酸, Pharmaceutical Secondary Standard; Certified Reference Material